AIM: To explore the role of Helicobacter pylori (H pylori) infection on the risk of digestive tract cancers. METHODS: In total, 199 oral squamous-cell carcinoma (SCC), 317 esophageal SCC, 196 gastric cardia and non-cardia adenocarcinoma and 240 colon adenocarcinoma patients were recruited for serum tests of H pylori infection. Two hospital- and one community-based control groups were used for the comparisons. H pylori seropositivity was determined by an enzyme linked immunosorbent assay method against H pylori IgG. RESULTS: Presence of H pylori infection was significantly inversely associated with esophageal SCC [adjusted odds ratio (AOR): 0.315-0.472, all P-value < 0.05] but positively associated with gastric adenocarcinoma (both cardia and non-cardia) (AOR: 1.636-3.060, all P-value < 0.05) in comparison to the three control groups. Similar results were not found in cancers of the oral cavity and colon. CONCLUSION: Our findings support the finding that H pylori seropositivity is inversely associated with esophageal SCC risk, but increases the risk of gastric cardia adenocarcinoma.
AIM: To explore the role of Helicobacter pylori (H pylori) infection on the risk of digestive tract cancers. METHODS: In total, 199 oral squamous-cell carcinoma (SCC), 317 esophageal SCC, 196 gastric cardia and non-cardia adenocarcinoma and 240 colon adenocarcinomapatients were recruited for serum tests of H pylori infection. Two hospital- and one community-based control groups were used for the comparisons. H pylori seropositivity was determined by an enzyme linked immunosorbent assay method against H pylori IgG. RESULTS: Presence of H pylori infection was significantly inversely associated with esophageal SCC [adjusted odds ratio (AOR): 0.315-0.472, all P-value < 0.05] but positively associated with gastric adenocarcinoma (both cardia and non-cardia) (AOR: 1.636-3.060, all P-value < 0.05) in comparison to the three control groups. Similar results were not found in cancers of the oral cavity and colon. CONCLUSION: Our findings support the finding that H pylori seropositivity is inversely associated with esophageal SCC risk, but increases the risk of gastric cardia adenocarcinoma.
Authors: P Limburg; Y Qiao; S Mark; G Wang; G Perez-Perez; M Blaser; Y Wu; X Zou; Z Dong; P Taylor; S Dawsey Journal: J Natl Cancer Inst Date: 2001-02-07 Impact factor: 13.506
Authors: A Hartwich; S J Konturek; P Pierzchalski; M Zuchowicz; H Labza; P C Konturek; E Karczewska; W Bielanski; K Marlicz; T Starzynska; M Lawniczak; E G Hahn Journal: Int J Colorectal Dis Date: 2001-08 Impact factor: 2.571
Authors: D A Corley; A Kubo; T R Levin; G Block; L Habel; W Zhao; P Leighton; G Rumore; C Quesenberry; P Buffler; J Parsonnet Journal: Gut Date: 2007-09-25 Impact factor: 23.059
Authors: Andrew D Jones; Kathy D Bacon; Blair A Jobe; Brett C Sheppard; Clifford W Deveney; Michael J Rutten Journal: J Gastrointest Surg Date: 2003-01 Impact factor: 3.452
Authors: Anna H Wu; Jean E Crabtree; Leslie Bernstein; Peter Hawtin; Myles Cockburn; Chiu-chen Tseng; David Forman Journal: Int J Cancer Date: 2003-03-01 Impact factor: 7.396
Authors: M T Wu; Y C Lee; C J Chen; P W Yang; C J Lee; D C Wu; H K Hsu; C K Ho; E L Kao; J M Lee Journal: Br J Cancer Date: 2001-09-01 Impact factor: 7.640
Authors: Michael J Morowitz; Trissa Babrowski; Erica M Carlisle; Andrea Olivas; Kathleen S Romanowski; John B Seal; Donald C Liu; John C Alverdy Journal: Ann Surg Date: 2011-06 Impact factor: 12.969
Authors: Ousman Secka; Martin Antonio; Mary Tapgun; Douglas E Berg; Christian Bottomley; Vivat Thomas; Robert Walton; Tumani Corrah; Richard A Adegbola; Julian E Thomas Journal: Gut Pathog Date: 2011-04-20 Impact factor: 4.181